tetano
Editor, Senior Moderator
Future Oncol
. 2021 Nov 26.
doi: 10.2217/fon-2021-0621. Online ahead of print.
Clinical and laboratory outcomes of the solid cancer patients reinfected with SARS-CoV-2
Oktay Ünsal[SUP] 1 [/SUP], Ozan Yazıcı[SUP] 1 [/SUP], Nuriye Özdemir[SUP] 1 [/SUP], Erdem Çubukçu[SUP] 2 [/SUP], Birol Ocak[SUP] 2 [/SUP], Aytuğ Üner[SUP] 1 [/SUP], Ahmet Özet[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test and those with improved clinical conditions after infection with COVID-19 were enrolled in this study. Patients who received a positive COVID-19 PCR test 28 days after the initial positive PCR test were considered as reinfected. Results: A total of 1024 patients with the diagnosis of solid malignancy and COVID-19 PCR positivity were examined. The reinfection rate was 3.1%. Mortality rate of reinfection was 34.3%. The serum ferritin and creatinine values in reinfection were found to be significantly higher than the first infection (respectively; p = 0.015, p = 0.014). Conclusion: This study has demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients.
Keywords: COVID-19; SARS-CoV-2; reinfection; solid cancer.
Plain Language Summary
Lay abstract Solid cancer patients are at a higher risk than general population in terms of Coronavirus disease 2019 (COVID-19) infectivity and COVID-19-associated death and disease. It is also known that COVID-19 infection has a more severe course in immunocompromised patients. Solid cancer patients may be a vulnerable subgroup of patients to reinfection with COVID-19. The rate of reinfection was 3.1% (n = 32) in our study population of 1024 solid cancer patients who were tested positive on a COVID-19 PCR test. The death rate of the patients with solid cancer was 34.3% (n = 11). In addition, we demonstrated that intensive care follow-up is significantly longer during the reinfection period. It was demonstrated that the time between the last dose of chemotherapy for the patients and the reinfection COVID PCR positivity did not affect the death rate. The COVID-19 pandemic has affected people's daily lives and treatments in many aspects. Owing to the high death rate of reinfection, even if cancer patients have reinfection, our approach is to continue cancer treatment as soon as the patient is cured. Finally, we support the priority vaccination of cancer patients.
. 2021 Nov 26.
doi: 10.2217/fon-2021-0621. Online ahead of print.
Clinical and laboratory outcomes of the solid cancer patients reinfected with SARS-CoV-2
Oktay Ünsal[SUP] 1 [/SUP], Ozan Yazıcı[SUP] 1 [/SUP], Nuriye Özdemir[SUP] 1 [/SUP], Erdem Çubukçu[SUP] 2 [/SUP], Birol Ocak[SUP] 2 [/SUP], Aytuğ Üner[SUP] 1 [/SUP], Ahmet Özet[SUP] 1 [/SUP]
Affiliations
- PMID: 34825831
- DOI: 10.2217/fon-2021-0621
Abstract
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test and those with improved clinical conditions after infection with COVID-19 were enrolled in this study. Patients who received a positive COVID-19 PCR test 28 days after the initial positive PCR test were considered as reinfected. Results: A total of 1024 patients with the diagnosis of solid malignancy and COVID-19 PCR positivity were examined. The reinfection rate was 3.1%. Mortality rate of reinfection was 34.3%. The serum ferritin and creatinine values in reinfection were found to be significantly higher than the first infection (respectively; p = 0.015, p = 0.014). Conclusion: This study has demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients.
Keywords: COVID-19; SARS-CoV-2; reinfection; solid cancer.
Plain Language Summary
Lay abstract Solid cancer patients are at a higher risk than general population in terms of Coronavirus disease 2019 (COVID-19) infectivity and COVID-19-associated death and disease. It is also known that COVID-19 infection has a more severe course in immunocompromised patients. Solid cancer patients may be a vulnerable subgroup of patients to reinfection with COVID-19. The rate of reinfection was 3.1% (n = 32) in our study population of 1024 solid cancer patients who were tested positive on a COVID-19 PCR test. The death rate of the patients with solid cancer was 34.3% (n = 11). In addition, we demonstrated that intensive care follow-up is significantly longer during the reinfection period. It was demonstrated that the time between the last dose of chemotherapy for the patients and the reinfection COVID PCR positivity did not affect the death rate. The COVID-19 pandemic has affected people's daily lives and treatments in many aspects. Owing to the high death rate of reinfection, even if cancer patients have reinfection, our approach is to continue cancer treatment as soon as the patient is cured. Finally, we support the priority vaccination of cancer patients.